Other mTORC1 inhibitors, such as rapamycin and its analogs, showed a better clinical response in cSCC than in BCC, probably due to the higher mTOR expression in SCC epidermal tissue (70, 75, 78, 120). Here, MTOR is linked to skin squamous cell carcinoma.